MSCs	Mesenchymal stem cells
CAR	Chimeric antigen receptor
SAR	Synthetic antigen receptor
PG	Recombinant protein G
EGFR	Epidermal growth factor receptor
NSCLC	Non-small-cell lung cancer
Cmab	Cetuximab
PLGA	Poly (DL-lactide–co–glycolide)
PA	Palmitic acid
NHS	N-hydroxysuccinimide
DPBS	Dulbecco’s phosphate-buffered saline
PA-PG	Palmitic-acid-derivatized protein G
UPLC-MS	Ultra-performance liquid chromatography–mass spectrometry
HPLC	High-performance liquid chromatography
IACUC	Institutional Animal Care and Use Committee
SCID	Severe combined immunodeficiency
IgG-MSCs (MSC + PTX NPs + IgG)	IgG-antibody-coated, paclitaxel-nanoparticle-loaded MSCs
Cmab-MSCs (MSC + PTX NPs + Cmab)	Cetuximab-coated, paclitaxel-nanoparticle-loaded MSCs
DMEM	Dulbecco’s modified Eagle’s medium
MTS	(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
LC/QTOF/MS	Liquid Chromatography/Quadrupole Time-of-Flight/Mass Spectrometry
RT-PCR	Reverse transcription–polymerase chain reaction
PMS	Phenazine methosulfate
CDRs	Complementarity-determining regions
AF647-IgG	Alexa Flour 647-labeled IgG
Cmab-MSCs	Cetuximab-modified MSCs
RPLP0	Ribosomal Protein Lateral Stalk Subunit P0
HER2	Human epidermal growth factor receptor 2
EphA2	Ephrin type-A receptor 2
IBD	Inflammatory bowel disease
mRNA	Messenger RNA
w/v	Weight/volume
FBS	Fetal bovine serum
NP	Nanoparticles
PTX	Paclitaxel
i.p.	Intraperitoneal
i.v.	Intravenous
Luc	Luciferase
Ab	Antibody
ex	Excitation
em	Emission
min	Minutes
h	Hour